Aims: The aim of this study was to examine the heterogeneity of cognitive dysfunction in Parkinson’s disease (PD) and to evaluate the contribution of cognitive criteria to the diagnosis of dementia in PD. Methods: In a sample of 100 consecutive PD patients with motor fluctuations, an extensive neuropsychological test battery was administered. Each PD patient’s cognitive profile was then compared with current cognitive criteria for dementia in PD. Results: Principal component analysis of the major test variables resulted in three components: one concerned with memory/attention, one with visuospatial, and one with executive/motor functions. Eighteen percent of our cohort showed no significant impairment on either domain. Fifty-one percent showed impairment in one cognitive domain, most frequently in the executive/motor component (88%). Twenty-four percent performed below normal on two cognitive components, most often executive/motor and memory/attention deficits (96%), and only 7% of our cohort had significant impairment on each derived cognitive component. Depending on the used criteria, 10–30% percent of our cohort could be categorized as PD patients with dementia. Conclusions: Future guidelines for a uniform diagnosis of dementia in PD are needed for clinical use and therapeutic management.

1.
Bosboom JLW, Stoffers D, Wolters EC: Cognitive dysfunction and dementia in Parkinson’s disease. J Neural Transm 2004;111:1303–1315.
2.
Dubois B, Pillon B, Malapani C, Deweer B, Vérin M, Partiaud A, Defontaines B, Sirigu A, Texeira C, Agid Y: Subcortical dementia and Parkinson’s disease: what are the cognitive functions of the basal ganglia? in Wolters EC, Scheltens P (eds): Mental Dysfunction in Parkinson’s Disease. Dordrecht, ICG Publications, 1994, pp 195–210.
3.
Cools R, Swainson R, Owen AM, Robbins TW: Cognitive dysfunction in non-demented Parkinson’s disease; in Wolters EC, Scheltens P, Berendse HW (eds): Mental Dysfunction in Parkinson’s Disease. Utrecht, Academic Pharmaceutical Productions BV, 1999, pp 142–164.
4.
Dubois B, Pillon B: Cognitive deficits in Parkinson’s disease. J Neurol 1997;244:2–8.
5.
Wolters EC, Francot CMJE: Mental dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 1998;4:107–112.
6.
Emre M: Dementia associated with Parkinson’s disease. Lancet Neurol 2003;2:229–237.
7.
Lieberman AN: Point of view. Dementia in Parkinson’s disease. Parkinsonism Relat Disord 1997;3:151–158.
8.
Aarsland D, Laake K, Larsen JP, Janvin C: Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708–712.
9.
Aarsland D, Mosimann UP, McKeith IG: Role of cholinesterase inhibitors in Parkinson’s disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17:164–171.
10.
Werber EA, Rabey JM: The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson’s disease and dementia. J Neural Transm 2001;108:1319–1325.
11.
Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P: Risk of dementia in Parkinson’s disease. A community-based, prospective study. Neurology 2001;56:730–736.
12.
Hobson P, Meara J: Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord 2004;19:1043–1049.
13.
Lang AE, Lozano AM: Parkinson’s disease. First of two parts. N Engl J Med 1998;8:1044–1053.
14.
Mindham RHS, Hughes TA: Cognitive impairment in Parkinson’s disease. Int Rev Psychiatry 2000;12:281–289.
15.
Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RHS, Spokes EGS: A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 2000;54:1596–1603.
16.
Dubois B, Pillon B: Dementia in Parkinson’s disease; in Wolters EC, Scheltens P, Berendse HW (eds): Mental Dysfunction in Parkinson’s Disease. Utrecht, Academic Pharmaceutical Productions BV, 1999, pp 165–176.
17.
Kaufer DI, Cummings JL: Dementia and delirium: an overview; in Feinberg TE, Farah MJ (eds): Behavioral Neurology and Neuropsychology. New York, McGraw-Hill, 1997, pp 499–520.
18.
Janvin CC, Aarsland D, Larsen JP: Cognitive predictors of dementia in Parkinson’s disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 2005;18:149–154.
19.
Levy G, Jacobs DM, Tang MX, Côté LJ, Louis ED, Alfaro B, Mejia H, Stern Y, Marder K: Memory and executive function impairment predict dementia in Parkinson’s disease. Mov Disord 2002;17:1221–1226.
20.
Mahieux F, Fénelon G, Flahault A, Manifacier MJ, Michelet D, Boller F: Neuropsychological prediction of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1998;64:178–183.
21.
Woods SP, Tröster AI: Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson’s disease. J Int Neuropsychol Soc 2003;9:17–24.
22.
Lezak MD: Neuropsychological Assessment, ed 3. New York, Oxford University Press, 1995.
23.
Hammes J: Stroop Kleur Woord Test. Handleiding. Amsterdam, Swets and Zeitlinger, 1971.
24.
Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G: Wisconsin Card Sorting Test. Manual Revised and Expanded. Odessa, Psychological Assessment Resources, 1993.
25.
Benton AL: Der Benton Test. Handbuch. Bern, Verlag Hans Huber, 1961.
26.
Warrington EK, Merle J: Visuele Perceptie van Object en Ruimte. Handleiding. Lisse, Swets and Zeitlinger, 1995.
27.
Schmand B, Lindeboom J, van Harskamp F: Nederlandse Leestest voor Volwassenen. Lisse, Swets and Zeitlinger, 1992.
28.
Beck AT, Steer RA: Beck Depression Inventory. Manual. San Antonio, The Psychological Corporation, 1993.
29.
Clark DA, Steer RA: Use of non-somatic symptoms to differentiate clinically depressed and non-depressed hospitalized patients with chronic medical illnesses. Psychol Rep 1994;75:1089–1090.
30.
Lannoo E, Vingerhoets G: Flemish normative data on common neuropsychological tests: influence of age, education and gender. Psychol Belg 1997;37:141–155.
31.
Spreen O, Strauss E: A compendium of neuropsychological tests. Administration, norms, and commentary. New York, Oxford University Press, 1998.
32.
Green J, McDonald WM, Vitek JL, Evatt M, Freeman A, Haber M, Bakay RAE, Triche S, Sirockman B, DeLong MR: Cognitive impairments in advanced PD without dementia. Neurology 2002;59:1320–1324.
33.
Caparros-Lefebvre D, Pécheux N, Petit V, Duhamel A, Petit H: Which factors predict cognitive decline in Parkinson’s disease? J Neurol Neurosurg Psychiatry 1995;58:51–55
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.